Juno Therapeutics’ in-development cancer immunotherapy notched a 91% complete remission rate in a small trial on children with a form of leukemia, an incremental victory for the company as it rolls into late-stage trials.

…read more

Source: Juno’s CAR-T contender comes through in another Phase I leukemia study


0 No comments